Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437642 | 0.85 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL3577069 | 0.82 | PTGS2 (0.41) | PTGS2PTGS1NPC1ALOX12NFKB1 | |
| SCHEMBL15459614 | 0.81 | RAB9A (0.44) | PTGS2NPC1ALOX12NFKB1RAB9A | |
| SCHEMBL13437655 | 0.76 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL3573107 | 0.76 | KDM4E (0.40) | PTGS2PTGS1RAB9ASMN1; SMN2 | |
| SCHEMBL13437645 | 0.74 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL14278512 | 0.73 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL12361481 | 0.71 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL12978741 | 0.70 | PTGS2 (0.70) | PTGS2PTGS1 | |
| Sulfamide SCHEMBL4639731 | 0.69 | PTGS2 (0.82) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | PTGS2 400/4885PTGS1 487/4885NPC1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.